|
1
|
Wittekind C, Compton CC, Greene FL and
Sobin LH: TNM residual tumor classification revisited. Cancer.
94:2511–2516. 2002.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
André T, Boni C, Mounedji-Boudiaf L,
Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan
P, Bridgewater J, et al: Multicenter International Study of
Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of
Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and
leucovorin as adjuvant treatment for colon cancer. N Engl J Med.
350:2343–2351. 2004.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sobrero A, Lonardi S, Rosati G, Di
Bartolomeo M, Ronzoni M, Pella N, Scartozzi M, Banzi M, Zampino MG,
Pasini F, et al: FOLFOX or CAPOX in Stage II to III Colon Cancer:
Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
J Clin Oncol. 36:1478–1485. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Gill S, Meyerhardt JA, Arun M and Veenstra
CM: Translating IDEA to Practice and Beyond: Managing Stage II and
III Colon Cancer. Am Soc Clin Oncol Educ Book. 39:226–235.
2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Galon J, Costes A, Sanchez-Cabo F,
Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M,
Berger A, Wind P, et al: Type, density, and location of immune
cells within human colorectal tumors predict clinical outcome.
Science. 313:1960–1964. 2006.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Broussard EK and Disis ML: TNM staging in
colorectal cancer: T is for T cell and M is for memory. J Clin
Oncol. 29:601–603. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Fridman WH, Pagès F, Sautès-Fridman C and
Galon J: The immune contexture in human tumours: Impact on clinical
outcome. Nat Rev Cancer. 12:298–306. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Galon J, Angell HK, Bedognetti D and
Marincola FM: The continuum of cancer immunosurveillance:
Prognostic, predictive, and mechanistic signatures. Immunity.
39:11–26. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Mei Z, Liu Y, Liu C, Cui A, Liang Z, Wang
G, Peng H, Cui L and Li C: Tumour-infiltrating inflammation and
prognosis in colorectal cancer: Systematic review and
meta-analysis. Br J Cancer. 110:1595–1605. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Mlecnik B, Tosolini M, Kirilovsky A,
Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman
WH, Pagès F, et al: Histopathologic-based prognostic factors of
colorectal cancers are associated with the state of the local
immune reaction. J Clin Oncol. 29:610–618. 2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Van den Eynde M, Mlecnik B, Bindea G,
Fredriksen T, Church SE, Lafontaine L, Haicheur N, Marliot F,
Angelova M, Vasaturo A, et al: The Link between the Multiverse of
Immune Microenvironments in Metastases and the Survival of
Colorectal Cancer Patients. Cancer Cell. 34:1012–1026.e3.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Pagès F, Mlecnik B, Marliot F, Bindea G,
Ou F-S, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al:
International validation of the consensus Immunoscore for the
classification of colon cancer: A prognostic and accuracy study.
Lancet. 391:2128–2139. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kerkar SP and Restifo NP: Cellular
constituents of immune escape within the tumor microenvironment.
Cancer Res. 72:3125–3130. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chen L: Co-inhibitory molecules of the
B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol.
4:336–347. 2004.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mahoney KM, Rennert PD and Freeman GJ:
Combination cancer immunotherapy and new immunomodulatory targets.
Nat Rev Drug Discov. 14:561–584. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Bethmann D, Feng Z and Fox BA:
Immunoprofiling as a predictor of patient's response to cancer
therapy-promises and challenges. Curr Opin Immunol. 45:60–72.
2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Salama P, Phillips M, Grieu F, Morris M,
Zeps N, Joseph D, Platell C and Iacopetta B: Tumor-infiltrating
FOXP3+ T regulatory cells show strong prognostic
significance in colorectal cancer. J Clin Oncol. 27:186–192.
2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sinicrope FA, Rego RL, Ansell SM, Knutson
KL, Foster NR and Sargent DJ: Intraepithelial effector
(CD3+)/regulatory (FoxP3+) T-cell ratio
predicts a clinical outcome of human colon carcinoma.
Gastroenterology. 137:1270–1279. 2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
deLeeuw RJ, Kost SE, Kakal JA and Nelson
BH: The prognostic value of FoxP3+ tumor-infiltrating
lymphocytes in cancer: A critical review of the literature. Clin
Cancer Res. 18:3022–3029. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Saito T, Nishikawa H, Wada H, Nagano Y,
Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, et
al: Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the
prognosis of colorectal cancers. Nat Med. 22:679–684.
2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Gabrilovich DI: Myeloid-Derived Suppressor
Cells. Cancer Immunol Res. 5:3–8. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Shipp C, Speigl L, Janssen N, Martens A
and Pawelec G: A clinical and biological perspective of human
myeloid-derived suppressor cells in cancer. Cell Mol Life Sci.
73:4043–4061. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Duan J, Xie Y, Qu L, Wang L, Zhou S, Wang
Y, Fan Z, Yang S and Jiao S: A nomogram-based immunoprofile
predicts overall survival for previously untreated patients with
esophageal squamous cell carcinoma after esophagectomy. J
Immunother Cancer. 6(100)2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Li F, Zhao Y, Wei L, Li S and Liu J:
Tumor-infiltrating Treg, MDSC, and IDO expression associated with
outcomes of neoadjuvant chemotherapy of breast cancer. Cancer Biol
Ther. 19:695–705. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Chen L and Han X: Anti-PD-1/PD-L1 therapy
of human cancer: Past, present, and future. J Clin Invest.
125:3384–3391. 2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Gong J, Chehrazi-Raffle A, Reddi S and
Salgia R: Development of PD-1 and PD-L1 inhibitors as a form of
cancer immunotherapy: A comprehensive review of registration trials
and future considerations. J Immunother Cancer. 6(8)2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ganesh K, Stadler ZK, Cercek A, Mendelsohn
RB, Shia J, Segal NH and Diaz LA Jr: Immunotherapy in colorectal
cancer: Rationale, challenges and potential. Nat Rev Gastroenterol
Hepatol. 16:361–375. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Marin-Acevedo JA, Dholaria B, Soyano AE,
Knutson KL, Chumsri S and Lou Y: Next generation of immune
checkpoint therapy in cancer: New developments and challenges. J
Hematol Oncol. 11(39)2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhai L, Ladomersky E, Lenzen A, Nguyen B,
Patel R, Lauing KL, Wu M and Wainwright DA: IDO1 in cancer: A
Gemini of immune checkpoints. Cell Mol Immunol. 15:447–457.
2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wang Y, Li J, Xia Y, Gong R, Wang K, Yan
Z, Wan X, Liu G, Wu D, Shi L, et al: Prognostic nomogram for
intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin
Oncol. 31:1188–1195. 2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Fong Y: Textbook Outcome Nomograms as
Multivariate Clinical Tools for Building Cancer Treatment Pathways
and Prognosticating Outcomes. JAMA Surg.
154(e190572)2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Camp RL, Dolled-Filhart M and Rimm DL: RL
C. X-tile: A new bio-informatics tool for biomarker assessment and
outcome-based cut-point optimization. Clin Cancer Res.
10:7252–7259. 2004.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Stack EC, Wang C, Roman KA and Hoyt CC:
Multiplexed immunohistochemistry, imaging, and quantitation: A
review, with an assessment of Tyramide signal amplification,
multispectral imaging and multiplex analysis. Methods. 70:46–58.
2014.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding
J, Zhu J, Wei H and Zhao K: Circulating and tumor-infiltrating
myeloid-derived suppressor cells in patients with colorectal
carcinoma. PLoS One. 8(e57114)2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Chen DS and Mellman I: Elements of cancer
immunity and the cancer-immune set point. Nature. 541:321–330.
2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Golstein P and Griffiths GM: An early
history of T cell-mediated cytotoxicity. Nat Rev Immunol.
18:527–535. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Pagès F, Kirilovsky A, Mlecnik B, Asslaber
M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P,
et al: In situ cytotoxic and memory T cells predict outcome in
patients with early-stage colorectal cancer. J Clin Oncol.
27:5944–5951. 2009.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Feng Z, Bethmann D, Kappler M,
Ballesteros-Merino C, Eckert A, Bell RB, Cheng A, Bui T, Leidner R,
Urba WJ, et al: Multiparametric immune profiling in HPV-
oral squamous cell cancer. JCI Insight. 2(2)2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Stromnes IM, Hulbert A, Pierce RH,
Greenberg PD and Hingorani SR: T-cell Localization, Activation, and
Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. Cancer
Immunol Res. 5:978–991. 2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Han Y, Liu D and Li L: PD-1/PD-L1 pathway:
Current researches in cancer. Am J Cancer Res. 10:727–742.
2020.PubMed/NCBI
|
|
43
|
Solinas C, De Silva P, Bron D,
Willard-Gallo K and Sangiolo D: Significance of TIM3 expression in
cancer: From biology to the clinic. Semin Oncol. 46:372–379.
2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Webb GJ, Hirschfield GM and Lane PJ: OX40,
OX40L and Autoimmunity: A Comprehensive Review. Clin Rev Allergy
Immunol. 50:312–332. 2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Weixler B, Cremonesi E, Sorge R, Muraro
MG, Delko T, Nebiker CA, Däster S, Governa V, Amicarella F, Soysal
SD, et al: OX40 expression enhances the prognostic significance of
CD8 positive lymphocyte infiltration in colorectal cancer.
Oncotarget. 6:37588–37599. 2015.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Xiao Z, Mayer AT, Nobashi TW and Gambhir
SS: ICOS Is an Indicator of T-cell-Mediated Response to Cancer
Immunotherapy. Cancer Res. 80:3023–3032. 2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Nakano M, Ito M, Tanaka R, Yamaguchi K,
Ariyama H, Mitsugi K, Yoshihiro T, Ohmura H, Tsuruta N, Hanamura F,
et al: PD-1+ TIM-3+ T cells in malignant
ascites predict prognosis of gastrointestinal cancer. Cancer Sci.
109:2986–2992. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Tay RE, Richardson EK and Toh HC:
Revisiting the role of CD4+ T cells in cancer
immunotherapy-new insights into old paradigms. Cancer Gene Ther.
28:5–17. 2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Merritt CR, Ong GT, Church SE, Barker K,
Danaher P, Geiss G, Hoang M, Jung J, Liang Y, McKay-Fleisch J, et
al: Multiplex digital spatial profiling of proteins and RNA in
fixed tissue. Nat Biotechnol. 38:586–599. 2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Kumar V, Patel S, Tcyganov E and
Gabrilovich DI: The Nature of Myeloid-Derived Suppressor Cells in
the Tumor Microenvironment. Trends Immunol. 37:208–220.
2016.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Sun HL, Zhou X, Xue YF, Wang K, Shen YF,
Mao JJ, Guo HF and Miao ZN: Increased frequency and clinical
significance of myeloid-derived suppressor cells in human
colorectal carcinoma. World J Gastroenterol. 18:3303–3309.
2012.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Limagne E, Euvrard R, Thibaudin M, Rébé C,
Derangère V, Chevriaux A, Boidot R, Végran F, Bonnefoy N, Vincent
J, et al: Accumulation of MDSC and Th17 Cells in Patients with
Metastatic Colorectal Cancer Predicts the Efficacy of a
FOLFOX-Bevacizumab Drug Treatment Regimen. Cancer Res.
76:5241–5252. 2016.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Nagaraj S, Nelson A, Youn JI, Cheng P,
Quiceno D and Gabrilovich DI: Antigen-specific CD4(+) T cells
regulate function of myeloid-derived suppressor cells in cancer via
retrograde MHC class II signaling. Cancer Res. 72:928–938.
2012.PubMed/NCBI View Article : Google Scholar
|
